Treatment Details – 10.5 months
|Patients: This Phase I study involved 13 patients with malignant mesothelioma.|
Treatment: The treatment consisted of a suspension of heat-killed Mycobacterium vaccae (SRL172), a fast growing avirulent mycobacterium, that may have non-specific immunomodulating properties in combination with standard chemotherapy (mitomycin-C (mitozytrex), vinblastine (velban) and cisplatin (platinol)).
Toxicity: Grade 1-3 toxicities included infection, emesis, mucositis, diarrhea, constipation, alopecia, neuropathy, fatigue, and hematological.
Results: The median overall survival was 10.5 months.
Support: This study was supported by a research grant from SR Pharma. SR Pharma markets SRL172.
Correspondence: MER O’Brien, MD